Gujarat Themis Biosyn Presents Q3 FY26 Investor Presentation
Gujarat Themis Biosyn reported Q3 FY26 revenue of ₹43.4 Cr (up 10% YoY) and PAT of ₹12.5 Cr. Nine-month PAT stood at ₹35.79 Cr. The company completed a new fermentation facility and is setting up a hybrid renewable power plant. R&D spend was 3% of revenue.
The investor presentation provides an update on financial performance and strategic initiatives, including capacity expansion and ESG efforts. While positive, it does not announce any immediate, transformative events that would drastically alter the company's trajectory in the short term.
The company reported positive year-on-year growth in revenue and EBITDA for Q3 FY26, along with progress in expansion and sustainability initiatives like the new fermentation facility and renewable power plant.
Gujarat Themis Biosyn Limited has submitted an investor presentation detailing its business overview for Q3 and the first nine months of FY2025-26.
In the third quarter of FY26, the company reported a 10% year-on-year increase in revenue to ₹43.4 crores. EBITDA grew by 12.9% to ₹21.31 crores, with a PAT of ₹12.5 crores. The EPS for the quarter was ₹1.14.
For the nine-month period ending FY26, total income from operations was ₹121.70 crores, with EBITDA at ₹56.17 crores and PAT at ₹35.79 crores. The company highlighted consistency in volumes, healthy demand, and stable margins due to cost optimizations. Key developments include the completion of a new fermentation facility, ongoing new product development with R&D spend at approximately 3% of revenue, and completion of validation batches for APIs. The company is also setting up a hybrid renewable power plant (wind-plus-solar) for captive consumption to reduce costs and its carbon footprint.
The presentation also covered balance sheet highlights as of September 30, 2025, showing total equity and liabilities of ₹376.67 crores and total assets of ₹376.67 crores. Key financial ratios such as RoCE, RoA, and RoE for FY24-25 were also presented.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.